Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

AstraZeneca Licenses Gout Drug To Grünenthal For Up To $230 Million

XTALKS VITALS NEWS

Pharmaceutical Sales

The German drugmaker has also agreed to pay a small royalty on sales of the gout drug.

Share this!

June 6, 2016 | by Sarah Massey, M.Sc.

AstraZeneca continues to sell the rights to its gout drug, Zurampic, with German pharmaceutical company Grünenthal paying as much as $230 million for the rights in Europe and Latin America. The deal – the cost of which will be based on the completion of certain milestones – means that Grünenthal now has the commercial rights to the drug in all 28 members of the European Union, Switzerland, Iceland, Norway, Liechtenstein and South America. Tweet: AstraZeneca continues to sell the rights to its #gout drug, Zurampic http://ctt.ec/fYr0z+

“We are highly committed to the research, development and commercialization of innovative therapies that bring true benefits to patients,” said Dr. Eric-Paul Pâques, CEO, Grünenthal. “Zurampic is a strong addition to our existing portfolio of innovative therapies in the areas of inflammatory diseases and chronic pain. We will thus use our capabilities to provide patients in our markets with this innovative new medicine to better control their condition.”

Earlier this year, AstraZeneca sold its US rights for Zurampic to Ironwood Pharmaceuticals for $100 million in cash, with another $165 million in potential milestone payments. While Grünenthal has the option to begin production of the drug in 2021, for now AstraZeneca will continue to manufacture Zurampic.



The German drugmaker has also agreed to pay a small royalty on sales of the gout drug. AstraZeneca has been making a number of externalization deals in an effort to focus their investment capital on new oncology drugs, as well as other key treatment areas.

“Grünenthal has an established presence across European and Latin American markets and extensive expertise in inflammatory diseases,” said Luke Miels, Executive Vice President, Global Product and Portfolio Strategy, AstraZeneca. “This agreement allows us to further focus our resources on our strategic priorities.”

Amid declining sales of older drugs, AstraZeneca CEO Pascal Soriot has set a lofty revenue goal of $45 billion by the year 2023. The maximum $500 million from both externalization deals for Zurampic could help AstraZeneca on its way to meeting its revenue target.


Keywords: Commercial Rights, Pharmaceutical Sales, Gout


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Exclusion Criteria for Clinical Trials Poses Major Barrier to Patient Enrollment

August 17, 2017 - UT Southwestern researchers say that clinical investigators continue to increase the number of exclusion criteria, preventing more patients from participating in clinical trials.

Featured In: Clinical Trials News


Targeting Cellular Nitrogen Metabolism Could Offer a New Treatment for Pancreatic Cancer

August 17, 2017 - An enzyme involved in regulating the amount of nitrogen in the cell could be a new drug target for pancreatic cancer, according to researchers from Boston Children's Hospital and the Broad Institute of MIT and Harvard.

Featured In: Life Science News


Regeneron’s Drug for Respiratory Syncytial Virus Fails in Phase III Clinical Trial

August 16, 2017 - Biotechnology company Regeneron has announced it will not continue development of its antibody drug, suptavumab, after a failure in a Phase III clinical trial.

Featured In: Clinical Trials News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

One Patient’s Perspective on Clinical Trials

REGISTER FOR THESE WEBINARS

Planning and Conducting Trials of the Latest Immunotherapies


ISO 13485:2016 for Medical Device Manufacturers: Ensuring a Smooth Transition through Effective Preparation


Medical Devices: Reviewing Regulatory Changes in the US and EU


Moving Beyond Regulatory and Performance Metrics in Starting Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.